FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
This article was originally published in The Tan Sheet
Executive Summary
Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule
You may also be interested in...
FDA Generics Rule: Relevance To Pending NDAs May Need Clarification – Troy
Patent information in currently pending NDAs may not fall under the jurisdiction of FDA's final rule on generic drugs
FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
FDA's final rule to reform Hatch/Waxman requires an innovator company to test data to establish that a polymorph claimed in a patent is the same as the active ingredient in the NDA
Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity